v3.26.3
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
Private Placement Warrants
Public Warrants
At-The-Market Public Offering
Common Stock
Common Stock
Private Placement Warrants
Common Stock
Public Warrants
Common Stock
At-The-Market Public Offering
Additional Paid-In Capital
Additional Paid-In Capital
Private Placement Warrants
Additional Paid-In Capital
Public Warrants
Additional Paid-In Capital
At-The-Market Public Offering
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
Common stock, beginning balance (in shares) at Dec. 31, 2024         784,176,364                  
Beginning balance at Dec. 31, 2024 $ 912,363       $ 78       $ 2,768,605       $ (1,855,737) $ (583)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
Net loss (82,406)                       (82,406)  
Stock-based compensation 27,019               27,019          
Issuance of common stock upon exercise of stock options and vesting of early exercised stock options (in shares)         807,475                  
Issuance of common stock upon exercise of stock options and vesting of early exercised stock options 547               547          
Issuance of common stock upon the release of restricted stock units (in shares)         4,063,821                  
Issuance of common stock in at-the-market public offering, net of issuance cost (in shares)               246,167            
Issuance of common stock in at-the-market public offering, net of issuance costs       $ 1,994       $ 1       $ 1,993    
Vesting of early exercised stock options 13               13          
Other comprehensive income (loss) (89)                         (89)
Common stock, ending balance (in shares) at Mar. 31, 2025         789,293,827                  
Ending balance at Mar. 31, 2025 859,441       $ 79       2,798,177       (1,938,143) (672)
Common stock, beginning balance (in shares) at Dec. 31, 2024         784,176,364                  
Beginning balance at Dec. 31, 2024 912,363       $ 78       2,768,605       (1,855,737) (583)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
Net loss (808,306)                          
Common stock, ending balance (in shares) at Sep. 30, 2025         874,277,241                  
Ending balance at Sep. 30, 2025 896,452       $ 87       3,559,790       (2,664,043) 618
Common stock, beginning balance (in shares) at Mar. 31, 2025         789,293,827                  
Beginning balance at Mar. 31, 2025 859,441       $ 79       2,798,177       (1,938,143) (672)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
Net loss (324,674)                       (324,674)  
Stock-based compensation 26,558               26,558          
Issuance of common stock upon exercise of stock options and vesting of early exercised stock options (in shares)         886,924                  
Issuance of common stock upon exercise of stock options and vesting of early exercised stock options 421               421          
Issuance of common stock upon the release of restricted stock units (in shares)         3,736,901                  
Issuance of common stock in at-the-market public offering, net of issuance cost (in shares)         49,701,790     5,853,452            
Issuance of common stock in at-the-market public offering, net of issuance costs 290,163     40,968 $ 5     $ 1 290,158     40,967    
Vesting of early exercised stock options 275               275          
Issuance of common stock under the Employee Stock Purchase Plan (in shares)         1,148,609                  
Issuance of common stock under the Employee Stock Purchase Plan 5,022               5,022          
Other comprehensive income (loss) 118                         118
Common stock, ending balance (in shares) at Jun. 30, 2025         850,621,503                  
Ending balance at Jun. 30, 2025 898,292       $ 85       3,161,578       (2,262,817) (554)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
Net loss (401,226)                       (401,226)  
Stock-based compensation 30,232               30,232          
Issuance of common stock upon exercise of stock options and vesting of early exercised stock options (in shares)         1,209,289                  
Issuance of common stock upon exercise of stock options and vesting of early exercised stock options 1,252               1,252          
Issuance of common stock upon the release of restricted stock units (in shares)         3,051,514                  
Issuance of common stock in at-the-market public offering, net of issuance cost (in shares)               7,059,395            
Issuance of common stock in at-the-market public offering, net of issuance costs       100,910       $ 1       100,909    
Issuance of common stock upon achievement of EBITDA targets (in shares)           4,128,197 2,881,758              
Issuance of common stock upon exercise of public warrants   $ 70,468 $ 58,700             $ 70,468 $ 58,700      
Issuance of common stock in Blade acquisition (in shares)         5,325,585                  
Issuance of common stock in settlement of contingent consideration 75,943       $ 1       75,942          
Vesting of earnout shares 60,709               60,709          
Other comprehensive income (loss) 1,172                         1,172
Common stock, ending balance (in shares) at Sep. 30, 2025         874,277,241                  
Ending balance at Sep. 30, 2025 $ 896,452       $ 87       3,559,790       (2,664,043) 618
Common stock, beginning balance (in shares) at Dec. 31, 2025 915,076,698       915,076,698                  
Beginning balance at Dec. 31, 2025 $ 1,409,713       $ 91       4,193,684       (2,785,579) 1,517
Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
Net loss (109,950)                       (109,950)  
Stock-based compensation 41,161               41,161          
Issuance of common stock upon exercise of stock options and vesting of early exercised stock options (in shares)         691,952                  
Issuance of common stock upon exercise of stock options and vesting of early exercised stock options 512               512          
Issuance of common stock upon the release of restricted stock units (in shares)         5,003,139                  
Issuance of common stock in at-the-market public offering, net of issuance cost (in shares)         52,863,437                  
Issuance of common stock in at-the-market public offering, net of issuance costs 576,336       $ 6       576,330          
Issuance of common stock upon achievement of EBITDA targets (in shares)           7,000,000 3,174              
Issuance of common stock upon exercise of public warrants   $ 70,000 47     $ 1       $ 69,999 47      
Reclassification of Delta Warrant liability upon exercise 37,870               37,870          
Payment for capped call transactions (63,273)               (63,273)          
Other comprehensive income (loss) (4,705)                         (4,705)
Common stock, ending balance (in shares) at Mar. 31, 2026         980,638,400                  
Ending balance at Mar. 31, 2026 $ 1,957,711       $ 98       4,856,330       (2,895,529) (3,188)
Common stock, beginning balance (in shares) at Dec. 31, 2025 915,076,698       915,076,698                  
Beginning balance at Dec. 31, 2025 $ 1,409,713       $ 91       4,193,684       (2,785,579) 1,517
Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
Net loss $ (567,223)                          
Common stock, ending balance (in shares) at Sep. 30, 2026 1,013,047,718       1,013,047,718                  
Ending balance at Sep. 30, 2026 $ 1,746,816       $ 101       5,110,524       (3,352,802) (11,007)
Common stock, beginning balance (in shares) at Mar. 31, 2026         980,638,400                  
Beginning balance at Mar. 31, 2026 1,957,711       $ 98       4,856,330       (2,895,529) (3,188)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
Net loss (245,443)                       (245,443)  
Stock-based compensation 49,056               49,056          
Issuance of common stock upon exercise of stock options and vesting of early exercised stock options (in shares)         429,542                  
Issuance of common stock upon exercise of stock options and vesting of early exercised stock options 149               149          
Issuance of common stock upon the release of restricted stock units (in shares)         4,259,555                  
Issuance of common stock upon achievement of EBITDA targets (in shares)             297              
Issuance of common stock upon exercise of public warrants     3               3      
Issuance of common stock under the Employee Stock Purchase Plan (in shares)         1,193,455                  
Issuance of common stock under the Employee Stock Purchase Plan 8,191       $ 1       8,190          
Other comprehensive income (loss) (2,944)                         (2,944)
Common stock, ending balance (in shares) at Jun. 30, 2026         986,521,249                  
Ending balance at Jun. 30, 2026 1,766,723       $ 99       4,913,728       (3,140,972) (6,132)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
Net loss (211,830)                       (211,830)  
Stock-based compensation 51,717               51,717          
Issuance of common stock upon exercise of stock options and vesting of early exercised stock options (in shares)         391,713                  
Issuance of common stock upon exercise of stock options and vesting of early exercised stock options 299               299          
Issuance of common stock upon the release of restricted stock units (in shares)         3,537,805                  
Issuance of common stock in at-the-market public offering, net of issuance cost (in shares)               20,174,525            
Issuance of common stock in at-the-market public offering, net of issuance costs       $ 128,204       $ 2       $ 128,202    
Issuance of common stock upon achievement of EBITDA targets (in shares)             2,625              
Issuance of common stock upon exercise of public warrants     $ 27               $ 27      
Issuance of common stock in Blade acquisition (in shares)         2,419,801                  
Issuance of common stock in settlement of contingent consideration 16,551               16,551          
Other comprehensive income (loss) $ (4,875)                         (4,875)
Common stock, ending balance (in shares) at Sep. 30, 2026 1,013,047,718       1,013,047,718                  
Ending balance at Sep. 30, 2026 $ 1,746,816       $ 101       $ 5,110,524       $ (3,352,802) $ (11,007)